Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Takeda Gearing Up for Emerging Market Operations
August 29, 2012
- MTPC, Daiichi Sankyo to Launch DPP-4 Inhibitor Tenelia on Sept. 10
August 29, 2012
- Izumo, Former VP of Novartis Institutes for BioMedical Research, Appointed Head of Takeda’s MD Drug Discovery Unit
August 29, 2012
- JT’s Licensee Obtains US Approval for Combination Tablet Containing JTK-303
August 29, 2012
- Nichi-Iko Voluntarily Recalls Lansoprazole OD Tablets 15 mg
August 29, 2012
- Daiichi Sankyo, Eli Lilly Not to Apply for Prasugrel for ACS in the US, Europe
August 29, 2012
- Major US, European Pharmaceutical Makers Faced with “Patent Cliffs”
August 28, 2012
- Plavix Approved for STEMI: sanofi-aventis
August 28, 2012
- Strattera Approved as 1st Adult ADHD Treatment in Japan: Eli Lilly Japan
August 28, 2012
- Growject Approved for SGA Dwarfism: JCR
August 28, 2012
- Large Portfolio, Competitive Prices, High Quality to Be Key to Success in Generics Business: Mr Bourla of Pfizer
August 27, 2012
- Japanese Ethical Drug Market Expands by 2.1% in Apr-Jun 2012: IMS Japan
August 27, 2012
- Diovan Approved for Pediatric Hypertension; Japan’s 1st ARB Approved for Pediatric Indication: Novartis
August 27, 2012
- Kyowa Kirin Initiates PII trial of Mogamulizumab in Europe, the US
August 27, 2012
- Once-Daily Administration of Pentasa in Remission Phase Approved; Kyorin Pharmaceutical
August 27, 2012
- Deal with Mylan to Boost Pfizer’s Generic Lineup in Japan with Definite Impact on Competitors
August 27, 2012
- Kyowa Kirin, Otsuka Still Working Out Specifics for Cooperation in Field of Oncology
August 27, 2012
- Forest HD Considering Joint Venture in Indonesia
August 24, 2012
- Pfizer, Mylan Ink Strategic Collaboration in Japan Generics Biz; Aim for No. 3 in Market
August 24, 2012
- Azilva Ranked No. 1 for Third Consecutive Month in Both GP, HP Markets in July: Rep Track Survey
August 23, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…